Homocysteine-lowering trials for prevention of cardiovascular events: A review of the design and power of the large randomized trials
- 25 January 2006
- journal article
- review article
- Published by Elsevier BV in American Heart Journal
- Vol. 151 (2), 282-287
- https://doi.org/10.1016/j.ahj.2005.04.025
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- MTHFR 677C→T Polymorphism and Risk of Coronary Heart DiseaseJAMA, 2002
- Homocysteine and Risk of Ischemic Heart Disease and StrokeJAMA, 2002
- Total Homocysteine Lowering Treatment Among Coronary Artery Disease Patients in the Era of Folic Acid-Fortified Cereal Grain FlourArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Vitamin Intervention for Stroke Prevention (VISP) Trial: Rationale and DesignNeuroepidemiology, 2001
- The Effect of Folic Acid Fortification on Plasma Folate and Total Homocysteine ConcentrationsNew England Journal of Medicine, 1999
- Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trialsBMJ, 1998
- Homocysteine and vascular diseaseNature Medicine, 1996
- A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular DiseaseJAMA, 1995
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- Vitamin Status and Intake as Primary Determinants of Homocysteinemia in an Elderly PopulationJAMA, 1993